Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers
NCT06254495 · View on ClinicalTrials.gov ↗
Study Summary
This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infection. There are several types of lymphoma. This study will enroll people who have classical Hodgkin lymphoma (cHL), peripheral T cell lymphoma (PTCL), or diffuse large B cell lymphoma (DLBCL). This clinical trial uses a drug called PF-08046044/SGN-35C . The study drug is in testing and has not been approved for sale. This is the first time SGN -35C will be used in people. This study will test the safety of SGN-35C in participants with lymphoma. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. This study will have three parts. Parts A and B of the study will find out the best dose and dosing schedule for SGN-35C. Part C will use the dose found in parts A and B to find out how safe SGN-35C is and if it works to treat select lymphomas.
Conditions Studied
Interventions
- DRUG PF-08046044/SGN-35C
Study Locations (20)
Kansas
- The University of Kansas Cancer Center, Investigational Drug Services — Fairway
- University of Kansas Clinical Research Center — Fairway
- The University of Kansas Hospital Cambridge North Tower A — Kansas City
- The University of Kansas Hospital — Kansas City
- The University of Kansas Medical Center Medical Office Building — Kansas City
- The University of Kansas Cancer Center - Overland Park — Overland Park
- The University of Kansas Cancer Center - Indian Creek Campus — Overland Park
- University of Kansas Cancer Center — Westwood
Florida
- Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center — Coral Gables
- University of Miami Hospital and Clinics - Deerfield Beach — Deerfield Beach
- Sylvester Comprehensive Cancer Center - Hollywood — Hollywood
- University Of Miami Hospital and Clinics/Sylvester Comprehensive Cancer Center — Miami
- University Of Miami Hospitals And Clinics — Miami
- Sylvester Comprehensive Cancer Center - Kendall — Miami
California
- City of Hope (City of Hope National Medical Center, City Of Hope Medical Center) — Duarte
- IP Address: City of Hope Investigational Drug Services(IDS) — Duarte
- University of California, San Francisco Medical Center — San Francisco
Nebraska
- Nebraska Medicine - Bellevue Medical Center — Bellevue
- Nebraska Medical Center — Omaha
Missouri
- The University of Kansas Cancer Center - Lee's Summit — Lee's Summit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2024-05-28 |
| Est. Completion | 2029-04-18 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06254495
The ClinicalTrials.gov registry entry for NCT06254495 describes a study currently listed as active not recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, a wholly owned subsidiary of Pfizer, which has 51 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 4 conditions, with Hodgkin Disease appearing as the primary indexed condition, and to 1 intervention — of which PF-08046044/SGN-35C is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06254495 reports 20 study locations spanning 5 distinct geographic areas — top geographies include Kansas, Florida, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06254495 about?
NCT06254495 is a clinical study titled "A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers". This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infection. There are several types of lymphoma. This study will enroll people who have classical Hodgkin lymphoma (cHL), peripheral T cell lymphoma (PTCL), or diffuse large B cell lymphoma (DLBCL...
What is the current status of trial NCT06254495?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2024-05-28. Estimated completion is 2029-04-18.
What conditions does trial NCT06254495 study?
This clinical trial studies the following conditions: Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06254495?
The interventions under investigation include: PF-08046044/SGN-35C (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06254495?
This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 51 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06254495 being conducted?
This trial has 20 study locations across California, Florida, Kansas, Missouri, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.